<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721550</url>
  </required_header>
  <id_info>
    <org_study_id>CMNAER1</org_study_id>
    <nct_id>NCT02721550</nct_id>
  </id_info>
  <brief_title>A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC</brief_title>
  <official_title>A Perspective Phase II Trial of Sodium Glycididazole Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a perspective, multicenter,single arm, open label, Phase 2 study to evaluate the
      efficacy and safety of treatment with CMNa combined with preoperatie concurrent
      chemoradiotherapy in patients with locally advanced squamous cell esophageal carcinoma .
      Analyses of primary objective (pathologic Complete Response) will be done as defined in the
      protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary end ponit of this study is pathological complete response.And the primary
      hypothesis is the CMNa will improve patholofical response rate and thus improve OS、DFS.
      Assuming bilateral a=0.05, statistical power of 80%.The total sample size is 40 cases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic Complete Response</measure>
    <time_frame>1 months</time_frame>
    <description>TRG-cited from Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer, 73, 2680-2686, 1994.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sodium Glycididazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Glycididazole</intervention_name>
    <description>800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.</description>
    <arm_group_label>Sodium Glycididazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent prior to study entry

          2. Patients with ESCC in thoracic segment which is resectable（T2-3，N0-1，M0） confirmed by
             imaging and pathology or cytology;

          3. Patients have tumor lesions which can be objectively measured ,the length of
             tumor:≤8cm, the width of tumor:≤5cm;If the tumor cross the GEJ and violate the
             proximal stomach, the tumor must include esophagus and GEJ. The tumor is less than 2cm
             of the stomach

          4. Not infringe bronchial wall; no esophagus-tracheal fistula.

          5. normal bone marrow reserve: ANCcount ≥1500/mm3;platelet count
             ≥100,000/mm3,hemoglobin≥9g/dl

          6. normal hepatic funcion:bilirubin level ≤1.5×ULN;AST/ALT≤1.5×ULN

          7. normal renal function: serum creatinine≤1.5mg/dl and calculated creatinine clearance
             ≥60ml/min

          8. normal cardiac function

          9. ECOG PS of 0 or 1

         10. Expected lifetime≥3 months

         11. Subjects tumor tissue available for the relevant biomarker detection

        Exclusion Criteria:

          1. Female subject who is during pregnancy or lactation, and the subject who have
             fertility don't take effective contraception during study.

          2. Any mental illness or nervous system lesions or can't tell treatment response clearly
             (such as cerebrovascular accident sequelae)

          3. Any serious uncontrolled disease and infection, such as severe heart, liver, kidney
             diseases or diabetes, can't complete the treatment plan

          4. Patients who have other malignant lesions, except curable skin cancer (non- melanoma
             skin cancer),carcinoma in situ of cervix or serve disease cured for 5 years

          5. Primary lesions were multifocal

          6. Patients with distant metastasis. A small amount of stomach tumor violate GEJ or the
             distal esophageal.

          7. Patients who have obvious esophageal ulcers or have above moderate pains in chest-back
             or have symptoms of esophageal perforation

          8. received anti-cancer treatment of esophageal cancer before the group, including
             surgery, radiotherapy, chemotherapy (induction of chemotherapy before the group is
             greater than or equal to two cycles).

          9. Cervical esophageal cancer confirmed by iconography

         10. Not esophageal squamous carcinoma confirmed by pathology or cytology

         11. History of active hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinming Yu, Ph.D, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinming Yu, Ph.D, M.D</last_name>
    <phone>13806406293</phone>
    <email>sdyujinming@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ligang Xing, Ph.D, M.D</last_name>
    <phone>15553181309</phone>
    <email>xinglg@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qianfoshan Hospital of Shandong</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiandong Zhang</last_name>
      <phone>13583123486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital and Institute</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jining NO.1 People's Hospital</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peipei Wu</last_name>
      <phone>15853770581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng People Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingjun Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao Center Medical Group</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuezhen Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rizhao City People 's Hospital</name>
      <address>
        <city>Rizhao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yufeng Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fei Cheng People's Hospital</name>
      <address>
        <city>Tai'an</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyuan Zhao</last_name>
      <phone>13518688689</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>An Qiu People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuandong Wang</last_name>
      <phone>15605368369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospitalof Zibo</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Zhang</last_name>
      <phone>13345221111</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>February 11, 2017</last_update_submitted>
  <last_update_submitted_qc>February 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

